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ABSTRACT
Introduction International guidelines recommend 
pulmonary rehabilitation (PR) should be offered to adults 
living with chronic obstructive pulmonary disease (COPD), 
but PR availability is limited in Sri Lanka. Culturally 
appropriate PR needs to be designed and implemented in 
Sri Lanka. The study aims to adapt PR to the Sri Lankan 
context and determine the feasibility of conducting a future 
trial of the adapted PR in Sri Lanka.
Methods and analysis Eligible participants will be 
identified and will be invited to take part in the randomised 
controlled feasibility trial, which will be conducted in 
Central Chest Clinic, Colombo, Sri Lanka. A total of 50 
participants will be recruited (anticipated from April 2021) 
to the trial and randomised (1:1) into one of two groups; 
control group receiving usual care or the intervention 
group receiving adapted PR. The trial intervention is a 
Sri Lankan- specific PR programme, which will consist of 
12 sessions of exercise and health education, delivered 
over 6 weeks. Focus groups with adults living with COPD, 
caregivers and nurses and in- depth interviews with 
doctors and physiotherapist will be conducted to inform 
the Sri Lankan specific PR adaptations. After completion 
of PR, routine measures in both groups will be assessed 
by a blinded assessor. The primary outcome measure 
is feasibility, including assessing eligibility, uptake and 
completion. Qualitative evaluation of the trial using focus 
groups with participants and in- depth interviews with PR 
deliverers will be conducted to further determine feasibility 
and acceptability of PR, as well as the ability to run a 
larger future trial.
Ethics and dissemination Ethical approval was obtained 
from the ethics review committee of Faculty of Medical 
Sciences, University of Sri Jayewardenepura, Sri Lanka 
and University of Leicester, UK. The results of the trial will 
be disseminated through patient and public involvement 
events, local and international conference proceedings, 
and peer- reviewed journals.
Trial registration number ISRCTN13367735
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is a progressive disease character-
ised by airflow obstruction and breathless-
ness. COPD is a major cause of morbidity 
and mortality throughout the world, corre-
sponding to 6% of all deaths worldwide.1 
Further, more than 90% of COPD deaths 
occur in low- income and middle- income 
countries.2 The most recent estimate of COPD 
prevalence in South Asia was 6.3%3 with a 
prevalence in Sri Lanka of 10.5%,4 similar 
to the estimated global COPD prevalence of 
Strengths and limitations of this study
 ► This study is the first examining the feasibility and 
acceptability of a culturally appropriate pulmonary 
rehabilitation programme for adults with chronic ob-
structive pulmonary disease in Sri Lanka.
 ► Taking a mixed- method approach, this study will 
provide a rich insight into delivering a trial of pulmo-
nary rehabilitation in the Sri Lankan context.
 ► This study is a single- centre feasibility trial. As 
such, while findings will be an important first step 
in understanding the potential role of pulmonary re-
habilitation in Sri Lanka and low- income and middle- 
income countries more broadly, findings may not be 
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11.7%.5 COPD is a significant burden to both patients 
and healthcare services.6
Chronic cough with sputum, breathlessness, phys-
ical inactivity and exercise intolerance resulting from 
dyspnoea or fatigue are common consequences of 
COPD.1 Symptoms of COPD progressively worsen and 
people can become breathless, even at rest. Daily activ-
ities often become difficult as the condition worsens, 
impacting their quality of life.7 The impact of COPD to 
the individual and to society makes the need for inter-
ventions to reverse the associated disability of paramount 
importance.
International guidelines recommend that pulmonary 
rehabilitation (PR) should be routinely offered to patients 
with chronic respiratory disease who have persistent 
symptoms, limited activity and/or are unable to adjust 
to illness.8 9 It is a low- cost, high- impact intervention that 
improves the quality of life, reduces suffering, reduces 
mortality and reduces economic loss, relieves dyspnoea 
and fatigue, improves exercise capacity, improves psycho-
logical and emotional function, and enhances an indi-
vidual’s self- management of their condition.1 Having 
realised the benefits of PR in COPD, Western countries 
have incorporated this as an important structural compo-
nent of healthcare delivery services.10 Implementation of 
PR based as practiced in Western countries, in Sri Lanka 
requires adaptation to the local health service, popula-
tion and culture. Despite its effectiveness, there is a signif-
icant need to understand the feasibility of conducting PR 
in low- resource Sri Lankan healthcare setting and the 
acceptability of PR among Sri Lankan adults living with 
COPD and healthcare staff involved in its delivery. Uptake 
and completion of PR even in Western countries is an 
ongoing challenge.11 The need to maximise appeal of PR 
to patients and referrers is a global issue and one that is 
likely to be specific to a given location and population. 
There remains an unmet need for PR in Sri Lanka. To be 
successful, PR must be not only evidence based, but also 
designed and implemented in a manner sensitive to the 
context in which it is being delivered, such as culture and 
geography. Therefore, the aim of this study is to devise 
an appropriate PR programme and then determine the 
feasibility and acceptability of this programme for adults 
living with COPD in Sri Lanka and assess the potential for 
a future trial of its effectiveness.
The objectives of the study are to:
1. Explore the needs and perceptions of adults living 
with COPD, their caregivers/family members and 
healthcare professionals to inform the adaptations re-
quired for a PR programme suitable for the Sri Lankan 
context.
2. Determine the feasibility of conducting adapted 
hospital- based PR for people living with COPD.
3. Assess the acceptability of the PR among Sri Lankan 
adults living with COPD and healthcare staff involved 
in its delivery.
4. Describe any changes in health of the adults living with 
COPD following completion of PR.
5. Assess the feasibility of a future trial and estimate the 
required sample size.
METHODS AND ANALYSIS
Study design and registration
The proposed study will be conducted in three phases. 
Phase 1: a qualitative study will be conducted to inform 
the adaptations required to make PR specific to the Sri 
Lankan context. Phase 2 is a single- blind randomised 
control feasibility trial. Adults living with COPD will be 
randomised (1:1) into adapted PR or usual care. Phase 
3: qualitative evaluation of the trial to determine the 
feasibility and acceptability of PR deliverers and partici-
pants. The trial will be conducted, analysed and reported 
according to the Standard Protocol Items: Recommen-
dations for Interventional Trials statement12 and trial 
has been registered on the ISRCTN website. Study was 
started on ethical approval on 24 July 2020 for phase 1 of 
the study. The design of the study and flow of participant 
enrolment is presented in figure 1.
Study setting
The study will be carried out at the Central Chest Clinic, 
Colombo, Sri Lanka, which is a leading healthcare facility 
that provides treatment for adults with respiratory disease. 
A room allowing confidential discussions will be used for 
conducting focus group discussions among adults living 
with COPD, their caregivers /family members, and nurses. 
Semistructured interviews will be conducted among 
doctors and physiotherapists in a given quite room at the 
Central Chest Clinic as convenient to them and without 
interfering with their routine work. The venue for PR will 
be a large room at the Central Chest Clinic.
Participants
Key informants and suitable participants for phase 1 of 
the study will be identified by the researchers with the 
help of healthcare professionals involved in the treat-
ment of COPD at Central Chest Clinic. Suitable partici-
pants will be purposively selected and informed verbally 
about the study by the researchers. After receiving a 
study information sheet, potential participants will be 
contacted to arrange an appointment, if they wish to take 
part. An opportunity to ask questions will be provided. 
If willing to take part in the study, they will be asked to 
provide written informed consent. Multireligious and 
multiethnic Sri Lankan cultural diversity and gender will 
be considered when recruiting to the study. Adults living 
with COPD aged ≥18 years and Medical Research Council 
(MRC) dyspnoea score grade 2 or higher, family member 
aged ≥18 years and looks after a patient with COPD and 
healthcare professionals who have more than 1- year expe-
rience of managing patients with COPD and working in 
the government healthcare system of the country will be 
eligible to participate in the phase 1 of the study. Partic-
ipants who provide written informed consent will be 





































































































































Sri Lankan specific adaptation of the PR 
Doctors and Physiotherapists Adults living with COPD, 
Family caregivers and  
Nurses  
Central Chest Clinic,  
Colombo, Sri Lanka 
Eligible adults provided 
information sheet  
 
Written informed 
consent obtained  
 
Baseline data collection 
  Randomisation (1:1) 
Usual Care  PR + Usual Care  
Post intervention data 
collection 
 
PR participants  
 
Staff involved in 
delivering PR 
 
Book of testimonies and 
evaluation form 
 





Recorded on a 
study 
screening log 







Feasibility and acceptability of the Sri Lankan specific PR 
 










Focus group discussions 






















































































































4 Jayamaha AR, et al. BMJ Open 2020;10:e041677. doi:10.1136/bmjopen-2020-041677
Open access 
After the adaptation of PR in phase 1, suitable partic-
ipants for the phase 2 randomised controlled feasibility 
trial will be identified by the medical officers in the Chest 
Clinic and will be invited to take part in an eligibility assess-
ment. This assessment will determine eligibility for entry 
into the study. People eligible for inclusion in the trial 
will be: aged ≥18 years, will have a clinically confirmed 
diagnosis of COPD by a physician, confirmed COPD with 
spirometry based on GOLD criteria with forced expi-
ratory volume in the first second (FEV
1
)/forced vital 
capacity (FVC)<0.7, and FEV
1
 <80% predicted, ≥1 exac-
erbation required a hospitalisation in the year preceding 
study, mMRC grade ≥2 and willing to provide informed 
consent. Adults with comorbidities such as severe or 
unstable cardiovascular, other internal diseases and loco-
motor difficulties that preclude the exercise or malignant 
disease or other serious illness which will interfere with 
participation in the PR, will be excluded from the study. 
Individuals not eligible for the study will be recorded on 
a study screening log.
Procedure
Eligible participants will be informed verbally about the 
study by the medical officers of the Central Chest Clinic. 
After receiving a study information sheet, potential partic-
ipants will be contacted to arrange an appointment, if they 
wish to take part. An opportunity to ask questions will be 
provided. If willing to take part in the study, they will be 
asked to provide written informed consent. Information 
regarding the interest of participation in the study will 
be taken as field notes. Baseline outcome measures will 
be assessed. After baseline data collection, participants 
will be randomised (1:1) into two groups. One group 
will receive usual care and PR and the other group will 
receive only usual care which consists of pharmacological 
treatment and brief information about disease condition, 
medication and inhaler techniques. Experiences of the 
participants and PR deliverers regarding the acceptability 
and feasibility of PR will be explored in interviews and 
focus groups during phase 3 of the study. Participants 
who did not complete the PR will be asked to take part in 
a drop- out interview and information provided freely by 
the participants will be collected as field notes.
Trial interventions
Intervention: adapted PR
Sri Lankan- specific PR will comprise the core elements 
of an evidence- based rehabilitation, a programme of 
exercises13 14 and health education.13–15 The detail of 
delivery and adaptations of PR will be informed by find-
ings of the phase 1 of the study. PR is typically a 6- week 
rolling programme that consists of 12 sessions in total.13 14 
Sessions usually last approximately 2 hours, with 1 hour 
for exercise training and 1 hour for education. All the 
education sessions and the instructions during PR will 
be provided in Sinhala language as convenient to the 
participants. The duration of the PR trial and frequency 
and duration of sessions will be discussed during phase 
1. All staff delivering PR will be trained and assisted by a 
nursing officer, a clinical nutritionist, an exercise physi-
cian and a physiotherapist. The venue for PR will be at the 
Central Chest Clinic, Colombo, Sri Lanka. The Central 
Chest Clinic will have a maximum capacity of 10 patients 
per PR class. The equipment required will be simple and 
include chairs, weights and simple exercise equipment 
based on local availability, suitability and informed by 
qualitative work.16
In keeping with evidence- based guidelines,13 14 discus-
sions in phase 1 will include the core exercise compo-
nent of PR, notably resistance training (eg, upper and 
lower limbs) and aerobic training (walking, sit- to- stand, 
step- ups) using minimal equipment and education. 
Each participant’s exercise regimen will be individually 
prescribed and progressed17 with walking speed will be 
prescribed using the Incremental Shuttle Walking Test 
(ISWT).18 The process in which this is achieved by patients 
will be informed by phase 1. The education component 
will be delivered by an interdisciplinary team and will be 
informed by qualitative findings from phase 1 with discus-
sions facilitated by usual education topics as described in 
guidelines.13 14
Usual care
Usual care will consist of pharmacological treatment and 
optimisation, prescribed to patients after consultation 
with medical officers at the Central Chest Clinic. Brief 
information about disease condition, medication and 
inhaler techniques will be provided by medical officers 
and nurses. PR or any form of exercise recommendation 
is not part of usual care.
Outcomes
Primary outcome
The primary outcome of the trial will be the feasibility 
and the acceptability of the PR intervention.
Feasibility
Measures to assess feasibility are provided in table 1 and 
include the comprehensive assessment of the feasibility of 
patient recruitment and the intervention delivery.
Acceptability
The acceptability of the PR intervention among adults 
living with COPD and healthcare staff involved in its 
delivery will be assessed. Participants’ experience of 
the PR, including any perceived benefits, challenges 
and changes they would make to the programme, will 
be explored in qualitative interviews and focus groups 
after their discharge assessment or withdrawal. The 
experience of healthcare professionals regarding the 
PR intervention, such as their confidence in delivering 
the programme, the components of PR, structure of 
PR, the patient adherence to the PR exercises and how 
their perceptions changed over the course of the trial, 
insights into barriers and facilitators to referral, uptake 
and completion of PR ((1) attending at least 10 out of 12 
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evaluation) will be explored in qualitative interviews at 
the end of the trial.
Secondary outcomes
The secondary outcomes of this study are provided in 
table 2. Comparison of secondary outcome measures of 
baseline and post intervention will describe any changes 
in the health of the adults living with COPD following 
completion of PR.
Sample size and recruitment target
This study is a feasibility trial that aims to provide data 
for an accurate estimation of the required sample size 
for future trials. Therefore, a formal sample size calcula-
tion is not required. We aim to recruit and randomise 50 
participants to the study (25 in each group).
Patient allocation, concealment and blinding
Randomisation will occur through random permuted 
blocks to either the intervention group (PR +usual care) 
or control group (usual care) in ratio 1:1 using Sealed 
envelope.
The computer- generated patient allocation sequence 
will be monitored by an individual who is independent 
of the research team and will inform the research team 
of group allocations via telephone. Participants will be 
informed about their group allocation after providing 
informed consent and completing baseline assessments.
It will not be possible to blind patients to their group 
allocation due to the nature of PR. Research staff will be 
blinded to outcome measures. Participants will be advised 
not to reveal their group during the follow- up assessment. 
Any episodes of unblinding will be documented and 
reported.
Data collection
Phase 1: Qualitative assessment for adaptation of PR
Focus groups with patient and family caregivers
Focus groups with adults living with COPD and sepa-
rate focus groups with their family members/caregivers 
will be conducted until data saturation. We anticipate 
conducting up to 5 focus groups with 6–8 participants in 
each. Data will be collected during patients’ clinic visits. 
Focus group discussions will be audio recorded, expected 
to last approximately 45–90 min, and will be conducted 
face to face by an interviewer and note- taker (observer). 
Focus groups will be transcribed verbatim, with identifi-
able information removed. Envisaged outcomes of the 
focus groups will include Sri Lankan specific adaptation 
of PR.
Interviews with healthcare professionals involving the treatment of 
COPD
Up to 15 in- depth interviews with healthcare profes-
sionals will be conducted until data saturation. Structured 
Table 1 Primary outcome measures—feasibility and operational experience assessment
Feasibility of patient recruitment Data sources
Feasibility of screening and recruiting participants Interviews with the healthcare professionals, screening log
Suitability of the inclusion criteria Interviews with the healthcare professionals, screening log
Number of eligible patients, number of patients screened, 
number of patients invited to take part, actual number of 
participants who consent to take part
Screening log
Number of patients who refuse, drop out and the reasons for 
refuse and drop out
Interviews with the patients, screening log
Operational experience of intervention delivery   
Service provider and multidisciplinary teams’ willingness and 
ability to deliver the PR
Interviews with healthcare professionals
The practicality of delivering the intervention in the proposed 
setting
Interviews with healthcare professionals and focus groups 
with participants
The time needed to collect the data
Baseline visit—time taken for each measure (each individual 
questionnaire and physical measure)
Follow- up visit—time taken for each measure (each individual 
questionnaire and physical measure)
Interviews with the healthcare professionals, rehabilitation 
records
Data completeness and accuracy Interviews with the healthcare professionals, rehabilitation 
records, RedCap
Adherence to home exercise Interviews with the patients and self- report exercise diary
The training and resources needed to deliver the intervention 
(ensuring readiness for a future much larger multicentre trial)
Interviews with the healthcare professionals and focus 
groups with participants, rehabilitation records
Description of unintended events Adverse events log, REDCap
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interviews will be conducted with healthcare profes-
sionals as convenient to them without interfering with 
their routine work. Interviews will be audio recorded and 
will be conducted face to face by an interviewer. Inter-
views will be transcribed verbatim, with identifiable infor-
mation removed. Envisaged outcomes of the in- depth 
interviews will be a suitable design and content of PR 
acceptable respiratory healthcare deliverers in Sri Lanka.
Phase 2: single-blind randomised control feasibility trial
Data will be collected by trained researchers, following 
standard operating procedures during participants’ clinic 
visits. Baseline and post intervention assessments will be 
carried out by the blinded medical officers consulting at 
the study setting.
Phase 3: qualitative evaluation of the PR intervention
Focus groups with patients
Participants allocated to the intervention group will be 
invited to participate in focus group discussions at the 
end of their PR programme. Focus groups will give an 
insight on views, experiences, opinions and recommen-
dations which will inform future PR programmes. We 
anticipate conducting up to five focus groups until data 
saturation. Each focus group discussion will be conducted 
with 6–8 participants in each.
Focus group discussions will be audio recorded, 
expected to last approximately 45–90 min, and will be 
conducted by a trained moderator and a note- taker). 
Focus groups will be transcribed verbatim, with identifi-
able information removed. Consent will be obtained from 
participants prior to their involvement in focus groups.
Interviews with PR staff
Healthcare personnel involved in delivering PR will be 
invited to participate in in- depth interviews at the end of 
the study to discuss aspects of feasibility and acceptability, 
such as insights into barriers and facilitators to atten-
dance, logistical barriers of running a PR programme 
and their perceptions, confidence of programme delivery 
and patients’ experiences of the intervention. Details 
regarding previous experience on PR and prior training 
regarding PR will be assessed using brief questionnaire 
before commencing the in- depth interviews. We antic-
ipate conducting up to 15 interviews, each expected to 
last approximately 15–60 min. Interviews will be audio 
recorded and will be conducted face to face by a trained 
interviewer. Interviews will be transcribed verbatim, with 
identifiable information removed.
Book of testimonies and evaluation form
Participants within PR will be asked to log their experi-
ence of PR as they progress through the programme. This 
will be in the form of a PR log book accessible to partici-
pants before, during and after sessions, as well as a dedi-
cated evaluation form which will be provided as online 
supplemental material. Staff involved in PR will also 
receive the same evaluation form at the end of the study.
Sample characteristics
Basic demographics including age, sex, religion, nation-
ality, marital status, age of leaving full- time education, 
education level, ethnicity, employment status, monthly 
income, lung health, smoking status (packs per year), 
biomass fuel exposure, primary respiratory diagnosis, 
Table 2 Secondary outcome measures
Outcome measures Baseline Post intervention
Sociodemographics x
Lung health (spirometry data, smoking status, number of COPD 




Nutritional status (body mass index, mid upper arm circumference, skinfold 
thickness, self- report 7 days diet diary)
x x
Disease burden (MRC dyspnoea grade, CAT, CCQ) x x
Economic impact of disease (WPAI) x x
Quality of life (EQ- 5D- 5L) x x
Pittsburgh Sleep Quality Index (PSQI) x x
Psychological well- being (Hospital Anxiety and Depression Scale) x x
Physical function (5× sit- to- stand test) x x
Exercise capacity (ISWT, ESWT) x x
International Physical Activity Questionnaire (IPAQ) x x
Accelerometer assessed physical activity (ActiGraph wGT3x- BT) x x
CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; EQ- 5D- 5L, EuroQol Five 
Dimensions Five Levels; ESWT, Endurance Shuttle Walk Tests; ISWT, Incremental Shuttle Walk Test; MRC, Medical Research Council; WPAI, 
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time since diagnosis in years, secondary respiratory diag-
noses, family history of lung disease, comorbidities will be 
recorded at baseline.
Lung function





/FVC ratio), carboxyhaemoglobin test,19 
hospitalisations within the last 12 months, number of 
COPD exacerbations within the last 12 months, treat-
ments will be collected as the baseline data prior to the 
randomisation of participants.
Nutritional status
Height (Holtain stadiometer), weight (calibrated weight 
scale) will be measured and body mass index will be calcu-
lated. Mid upper arm circumference of the participants 
will be measured using a measuring tape and skinfold 
thickness of seven sites (triceps, mid axillary, subscapular, 
chest, abdominal, supra iliac and thigh measurements) 
of the body will be measured using a validated calliper. 
Triplicated measurements will be taken by the same 
investigator and mean value will be used for the calcu-
lation of body fat mass. Fat- free mass will be calculated 
using Durnin and Womersley formula.20 21 Body compo-
sition analysis will be assessed using bioelectrical imped-
ance (SFB7 Impedi Med dual frequency instrument, 
Impedi Med Limited, Australia) and software V.5.2.4.0.22 
Seven- day diet diary method will be used to assess the 
dietary history and calorie intake.
Disease burden
Breathlessness will be measured using MRC dyspnoea 
grade (5- item).23 The health- related quality of life related 
to mobility, self- care, usual activities, pain/discomfort and 
anxiety–depression will be measured using EuroQol Five 
Dimensions Five Levels (25- item).24 Clinical status of the 
airways, functional limitations and psychosocial dysfunc-
tion will be determined using Clinical COPD Question-
naire (10- item).25 COPD Assessment Test (8- item) will 
be used to determine the severity of the COPD.26 Modi-
fied brief pain inventory (3- item) will determine the 
commonly reported chest pain; Work Productivity and 
Activity Impairment questionnaire (8- item) will be used 
to measure the effect of severity of COPD and general 
health on work productivity and regular activities27 and 
Hospital Anxiety and Depression Scale (14- items) will 
be used to measure the patient’s emotional state and 
the presence or absence of clinically significant anxiety 
and depression.28 Sleep quality of the participants will be 
measured using Pittsburgh Sleep Quality Index.29 Disease 
burden will be measured as baseline data prior to the 
randomisation and postintervention data.
Exercise capacity
Following a safety assessment for absolute and rela-
tive contraindications for field walking tests,30 maximal 
exercise capacity will be assessed using the ISWT31 and 
Endurance Shuttle Walking Test (ESWT).18 The ISWT 
and ESWT also include a pretest and post- test measure 
of SpO
2
, blood pressure, Borg rating of breathlessness,32 
heart rate, Borg rate of perceived exertion.33 The sit- to- 
stand test will be completed for five continuous repeti-
tions, to measure lower limb movement and strength.34 
All measures of exercise capacity will be measured at base-
line prior to the randomisation and post intervention.
Physical activity
Subjective health- related physical activity will be measured 
with the International Physical Activity Questionnaire35 at 
baseline prior to the randomisation and post intervention.
Participants will be asked to wear an activity monitor 
(ActiGraph wGT3X- BT, ActiGraph, Pensacola, Florida, 
USA), able to detect a range of PA intensities,36 on the 
right anterior hip during waking hours for 7 days prior 
to attending PR (baseline) and for the 7 consecutive days 
prior to their discharge assessment (follow- up); taking it 
off for water- based activities and sleep. The collection of 
physical activity data will coincide with a 7 days diet diary. 
Printed instructions will be provided to the participants 
regarding how to wear the monitor.
Full accelerometry methodology is provided in table 3. 
Data will be processed as 60 s epoch files in ActiLife 
V.6.13.4 (ActiGraph). Non- wear will be defined as 60 min 
of consecutive zero counts with allowance for 2 min of 
interruptions.37 Adherence to wearing the monitors will 
be assessed by examining the proportion of participants 
providing valid accelerometer data across a range of 
valid days (≥1–7 days) and minimum wear time (≥1–12 
hours) thresholds. For reported group averages, only 
participants providing ≥4 valid days of ≥8 hours, for both 
time points will be included in the analyses.38 Step count, 
time spent in different absolute intensity classifications 
of physical behaviours39 and average movement intensity 
(activity counts per minute) will be reported. Time spent 
in physical activity matching participants’ prescribed 
walking exercise intensity will be derived by aligning the 
average walking speed during the ESWT with the activity 
monitor counts per minute and cadence.
Patient and public involvement
Adults living with COPD often tell us how having COPD 
impacts their lives and that they often find it challenging 
to know what they can do to better manage their condi-
tion. When they talk about their self- management strat-
egies, it is clear that education and exercise support 
would be of value. Also, they revealed the necessity of a 
programme to support their condition and willingness to 
attend such a programme. Patients are generally positive 
about being able to access support but there is little avail-
able to them. The study was planned to fulfil the need of 
adults living with COPD. The delivery and adaptations of 
the trial intervention (Sri Lankan- specific PR) will also be 
informed by the adults living with COPD, their caregivers/
family members and healthcare professionals. Priorities, 
experience and preferences of the stakeholders will be 
used to design the PR. Healthcare professionals involved 
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be involved in the recruitment as key informants and 
conduct of the study. The feasibility and acceptability of 
the PR intervention among adults living with COPD and 
healthcare staff involved in its delivery will be assessed in 
qualitative interviews at the end of the trial. The results of 
the trial will be disseminated through patient and public 
involvement events, local and international conference 
proceedings. As well as all the research participants, 
stakeholders and individuals with COPD will be openly 
invited to take part in an event organised at the central 
chest clinic to reveal the study findings.
Costing
As part of this trial, the cost of creating a Sri Lankan- 
adapted PR programme will be calculated. This will include 
both single and recurrent costs. Single payments include 
the necessary costs to set up and run a programme, while 
recurrent cost refers to any item with a life expectancy of 
1 year or less and typically includes disposable materials.40 
The fixed costs will be captured prior to the first partic-
ipant enrolling into the programme and the recurrent 
costs will be collected at the mid- stage of recruitment. An 
average cost per participant will be calculated. Table 4 
demonstrates the variables that will be used to calculate 
fixed and recurrent costs.
Data management
Data collected during the study will be entered into a data-
base using Research Electronic Data Capture (REDCap), 
which is a web- based platform.41 Access to the database 
will be via a secure password- protected web interface. The 
participants will be identified by a study- specific identifi-
cation code. Data will be validated using real- time data 
entry validation and electronic checks lead by the Inde-
pendent Data Monitoring Committee (IDMC), estab-
lished at the University of Leicester, UK.
Quantitative data analysis
The data will be analysed using IBM SPSS Statistics for 
Windows, V.23.0. Data for baseline and follow- up time-
points will be presented as descriptive statistics as appro-
priate. No inferential statistics will be performed due to 
the feasibility design of the trial.
Table 3 Accelerometry data collection and processing parameters
Accelerometer Model ActiGraph wGT3X- BT (V.6.13.4; firmware V.1.9.2)
Serial number range Twenty unique devices will be used ranging from MOS2E09190601 to MOS2E24190146 
averaging six deployments per device (same serial used for baseline and follow- up wear 
periods)
Piezosensor orientation Triaxial
Mode setup Mode 29 (x, y, z, steps, lux)
Original sample rate 100 Hz (.gt3x file format)
Deployment method Baseline:
Fitted by research team on day 0 (baseline PR assessment)
Fitted by participant on day 1
Follow- up:
Fitted by research team day 0 (11th/12th session)
Fitted by participant on day 1
Location worn Anterior hip adjacent to the mid- line of the thigh
Requested days of wear 7 days of free living (days 1–7; 10 080 epochs)
Initialisation Not deployed in delay mode in order to standardised capture of day 0 (00:00) with stop 
time based on date of first PR class (baseline) and data of discharge assessment (follow- 
up)
Wear instructions Wear continuously except for sleep and water- based activities
Non- wear appropriation ≥60 min of consecutive 0 s with allowance for 2 min of interruptions were deemed 
biologically implausible and coded as non- wear
Valid day criteria ≥8 hours of valid waking wear time
Valid file ≥4 valid days for each of the two time points
Missing data Data modelling or imputation will not be performed
Epoch length 60 s
Intensity classification (absolute) Uniaxial (x- axis) cut- points as follows: sedentary time <100 cpm; light intensity 100–2019 
cpm; moderate intensity 2020–5998 cpm; vigorous intensity ≥5999 cpm (moderate- to- 
vigorous intensity ≥2020 cpm)
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Qualitative data analysis
Qualitative data will be analysed using thematic anal-
ysis. This approach follows six distinct stages: familiari-
sation with data; generating initial codes; searching for 
themes; reviewing themes; defining and naming themes 
and producing the report.42 The responsible investi-
gator will carry out initial coding and a sample of focus 
group transcripts will be coded by a second member of 
the team to improve consistency and to enhance inter-
pretive authenticity. Throughout the data analysis, the 
team will meet to discuss and review emerging themes 
and search the accounts that provide contesting views of 
the same phenomena. Close attention will be paid to the 
complexity and interactions inherent in the focus group 
data.43
Adverse events
All adverse events and serious adverse events will be 
recorded on an adverse event log, within study trial 
management paperwork, case report forms and REDCap. 
There will be no formal interim analysis of data due to 
the feasibility nature of the trial. The IDMC will review 
high- level safety data. Adverse events will be monitored 
at least every month, and as needed on an ad hoc basis, 
to ensure the continuing safety of the participants. The 
scientific committee will determine the need to terminate 
the trial. Participants who experience any such event will 
be directed to the appropriate hospital and all the neces-
sary care will be ensured and followed up until the partic-
ipant has resolved or stabilised.
ETHICS AND DISSEMINATION
Ethical approval was obtained from the ethics review 
committee of the Faculty of Medical Sciences, University 
of Sri Jayewardenepura (FMS/USJP ERC 64/19) and the 
University of Leicester, UK (26770). Further permission 
for the proposed study will be obtained from the relevant 
authority at the Central Chest Clinic, Colombo. Sri Lanka. 
Privacy and the confidentiality of all information and 
identities of participants will be strictly maintained and 
will not be disclosed when publishing the results of the 
study. A copy of the test results obtained will be provided 
to each participant at the end of the trial for subsequent 
follow- up and treatment at the clinic. Compensation 
for travelling will be provided to all the participants. All 
study documents will be translated to Sinhala and Tamil 
to ensure clear communication. Participation will be 
without compulsion and each participant has the right to 
withdraw at any time, without providing a reason. Consent 
form and data sheets will be securely stored in a sepa-
rate locked cupboard. Study computers will be password 
protected. The participants (adults living with COPD) of 
the phase 1 study also will be provided the opportunity 
to participate the PR. All the data will be stored safely up 
to 6 years and after 6 years consent form and data sheets 
will be disposed of appropriately. Study team and IDMC 
only will have access to final trial dataset. Data from the 
Global Health Research Group on Respiratory Rehabili-
tation (Global RECHARGE) Core Dataset 44 will be made 
available following the completion of this project and we 
are considering the best tools to use to make this database 
available to the wider community. Any modifications of 
the protocol will be updated on trial registry (ISRCTN) 
and will be informed to the ethics review committee and 
the participants. Participants will be provided the provi-
sions for reconsenting after any change of the approved 
protocol. It will be made clear in the publication of trial 
findings.
Table 4 The variables used to calculate fixed and recurrent costs (not an exhaustive list)
Fixed costs Recurrent costs
Venue hire Venue hire
Electrical equipment (laptop, printer, projector) Staff time to conduct PR (assessment at baseline and 
discharge, conduct PR classes, telephone calls and data 
entry)
Equipment for PR (weights, treadmill, cycle ergometer, country- 
specific equipment, step- up box, chairs)
Disposable equipment (for blood glucose monitor, 
spirometer mouthpieces, nose- clips, glyceryl trinitrate 
spray)
Equipment for shuttle walking tests (cones, licences, stop 
watches, tape measure, electrical equipment to play audio)
Servicing costs (spirometer, PR equipment, specifically 
treadmills and cycle ergometers)
Equipment for PR assessment (height stadiometer, weight scales, 
sphygmomanometer, pulse oximeter, spirometer, calibration 
syringe, country- specific equipment)
Miscellaneous (oxygen cylinders, questionnaire licences, 
stationery (paper))
Additional safety equipment (blood glucose monitor, oxygen 
cylinder holder)
  
Miscellaneous (filing cabinets, storage units, questionnaire 
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Appendices   
Information sheet 
Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised 
Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka 
 
I am Prof. S, W. Wimalasekera, of Department of Physiology, Faculty of Medical Sciences, University of 
Sri Jayewardenepura. I and my team of health care personnel are, conducting a research on “Testing the 
Feasibility and Acceptability of a Culturally Appropriate Hospital-Based Pulmonary Rehabilitation (PR) 
Programme for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka”. I invite you to 
participate in the study. Please take time and read the following information carefully before giving your 
consent. You are free to ask questions to clarify facts which are not clear or ask for more information if 
you need. 
 
Purpose of the study 
The purpose of this study is to devise an appropriate PR programme and then determine the feasibility 
and acceptability of this programme for adults living with COPD in Sri Lanka and assess the potential for 
a future trial of its effectiveness. 
 
When you participate you will be required to do the following 
You will be requested to participate several components of the study. 
You will participate in a group discussion conducted in a quiet room in the clinic (conference hall) with 
very minimal disturbances. At the beginning of the discussion you will answer some questions regards 
your personal information, (age, gender, history of the disease condition). Then the interviewer will ask 
some questions regarding your thoughts and ideas about pulmonary rehabilitation. You and your group 
members can freely comment on the questions or can add your ideas to the discussion. The interview 
takes around forty-five minutes of time. 
You will also participate in a feasibility trial which you will be allocated to one of the two groups. One 
group will receive usual care and PR and the other group will receive only usual care which consists of 
pharmacological treatment and brief information about disease condition, medication and inhaler 
techniques. PR is typically a 6-week rolling programme and consisting of 12 sessions in total, delivered 
twice a week. Sessions usually last approximately two hours, with one hour for exercise training and one 
hour for education. Some routine and specific test and measurements will be taken before and after the 
intervention will describe any changes in the health of the adults living with COPD. 
If you are allocated to the group who receive the PR, you will be asked to share your experiences 
regarding the PR and subjected modification and opinions on pulmonary rehabilitation. 
In order to maintain accuracy, and to keep records, your discussion will be recorded by the research team 
members with your permission. Your participation in the project will remain confidential and the 
provision of your name and address is necessary for us to maintain records. Any personal information 
gathered during the study will not be disclosed to a third party. Your responses to the questions and will 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-041677:e041677. 10 2020;BMJ Open, et al. Jayamaha AR
only be used for the purpose of this project. You can be assured that you will remain anonymous if you 
take part in the project. Your participation in this project is entirely voluntary. You are not obliged to take 
part. If you do not wish to take part, you can withdraw without giving a reason and your medical care will 
not be affected, further you will not be contacted again. Similarly, if you do agree to participate, you are 
free to withdraw at any time during the project. 
 
What are the possible benefits of taking part?  
By participating in the study, you will contribute to develop a PR programme which helps to improve the 
quality of life of the adults living with COPD. As well as you will contribute to determine the feasibility 
and acceptability of this programme within the health care system in Sri Lanka.  
 
What are the possible disadvantages and risks of taking part?  
You will be undertaking some physical tests as part of the research. Therefore, there may be a very small 
risk of falls, breathlessness, changes in blood pressure and changes in heart rate. However, these risks are 
very rare, and trained staff and emergency equipment will be available to deal with any serious events. 
Participants who experience any such event will be directed to the appropriate hospital and all the 
necessary care will be ensured and followed-up until the participant has resolved or stabilized.  
 
What will happen if you don’t carry on with the study?  
If you withdraw from the study all the information and data collected from you, to date, will be destroyed 
and your name would be removed from all the research study files. There will not be any loss or impact 
on your routine medical care which you are entitled to.  
 
What will happen to the results of the research study?  
The results of all the participants of the study will be used for scientific research. All data will be 
available only to the researchers and information provided will be strictly confidential. Your participation 
in the study is highly appreciated. Privacy and confidentiality of data gathered is completely secure and 
will be used only for research purposes. If you have any questions or any concerns with regards to the 
study and need further information you can call the telephone number listed below. Further you can send 
any complaint to the above postal address or email address. 
 
Yours faithfully  
Prof. S.W. Wimalasekera  
Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura  
T.P No. 0777487203 e-mail : savithriww@yahoo.com  
Ethics Review Committee – University of Sri Jayewardenepura - +94 11 2758000 Ext 4075e 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-041677:e041677. 10 2020;BMJ Open, et al. Jayamaha AR
Consent Form: Randomised Controlled Feasibility Trial  
Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised 
Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka 
1.Have you read the information sheet? (please keep a copy for yourself)  YES/NO  
2.Have you had an opportunity to discuss this and ask any questions?    YES/NO  
3. Have you had satisfactory answers to all your questions?     YES/NO  
4. Have you received enough information about the study?     YES/NO  
5. Who explained the study to you---------------------------------------------------------------------------------- 
6. Do you understand that you are free to withdraw from the study at any time,  
without having to give a reason        YES/NO  
7. All personal details will be treated as STRICTLY CONFIDENTIAL.  
Do you give your permission for these individuals to have access to the records?  YES/NO  
8. Have you had sufficient time to come to your decision?     YES/NO  
9. Do you agree to take part in this study?       YES/NO  
Participant’s signature ----------------------------------------    Date-------------------------  
 
By the Witness  
I have been present while the procedure was explained to the participant and I have witness his/ her  
willingness to take part in the study.  
Signature of witness--------------------------------------------------------  Date-------------------------------- 
(The witness should be a person not connected to the study)  
Name ----------------------------------------------------------------------------------------------------------------------  
Contact details------------------------------------------------------------------------------------------------------------ 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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and your name would be removed from all the research study files. There will not be any loss or impact 
on your routine medical care which you are entitled to.  
 
What will happen to the results of the research study?  
The results of all the participants of the study will be used for scientific research. All data will be 
available only to the researchers and information provided will be strictly confidential. Your participation 
in the study is highly appreciated. Privacy and confidentiality of data gathered is completely secure and 
will be used only for research purposes. If you have any questions or any concerns with regards to the 
study and need further information you can call the telephone number listed below. Further you can send 
any complaint to the above postal address or email address. 
 
Yours faithfully  
Prof. S.W. Wimalasekera  
Department of Physiology, Faculty of Medical Sciences, University of Sri Jayewardenepura  
T.P No. 0777487203 e-mail : savithriww@yahoo.com  
Ethics Review Committee – University of Sri Jayewardenepura - +94 11 2758000 Ext 4075e 
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Consent Form: Randomised Controlled Feasibility Trial  
Cultural adaptation of Pulmonary Rehabilitation and subsequent testing in a Randomised 
Controlled Feasibility Trial for Adults with Chronic Obstructive Pulmonary Disease in Sri Lanka 
1.Have you read the information sheet? (please keep a copy for yourself)  YES/NO  
2.Have you had an opportunity to discuss this and ask any questions?    YES/NO  
3. Have you had satisfactory answers to all your questions?     YES/NO  
4. Have you received enough information about the study?     YES/NO  
5. Who explained the study to you---------------------------------------------------------------------------------- 
6. Do you understand that you are free to withdraw from the study at any time,  
without having to give a reason        YES/NO  
7. All personal details will be treated as STRICTLY CONFIDENTIAL.  
Do you give your permission for these individuals to have access to the records?  YES/NO  
8. Have you had sufficient time to come to your decision?     YES/NO  
9. Do you agree to take part in this study?       YES/NO  
Participant’s signature ----------------------------------------    Date-------------------------  
 
By the Witness  
I have been present while the procedure was explained to the participant and I have witness his/ her  
willingness to take part in the study.  
Signature of witness--------------------------------------------------------  Date-------------------------------- 
(The witness should be a person not connected to the study)  
Name ----------------------------------------------------------------------------------------------------------------------  
Contact details------------------------------------------------------------------------------------------------------------ 
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